Syner-G BioPharma Group
Gregory Demos has a diverse work experience that includes roles as a Staff Accountant at Syner-G BioPharma Group, an Intern in the Executive Office of Housing and Economic Development at the Commonwealth of Massachusetts, and two internships at the MetroWest Economic Research Center (MERC). At Syner-G BioPharma Group, Gregory prepared journal entries and balance sheet reconciliations, managed cash activity, and assisted with NetSuite requests and vendor payables. As an intern with the Commonwealth of Massachusetts, they analyzed Paycheck Protection Program loan data and prepared Excel graphs and reports for the Massachusetts Governor and Secretary of Housing and Economic Development. During their time at MERC, Gregory created articles and graphs displaying economic data, prepared presentations for business leaders, mentored and trained junior interns, and gathered and analyzed economic data for local community economic development.
Gregory Demos attended Framingham State University from 2018 to 2022, where they earned a Bachelor of Science degree in Accounting.
Syner-G BioPharma Group
Syner-G BioPharma Group provides in-depth expertise across the three key elements of Chemistry, Manufacturing, and Controls (CMC): Regulatory Services, Technical Development, and Quality/IT. We call this CMC 360™. We also provide medical writing services, with expertise in authoring a variety of regulatory documents across a wide range of therapeutic areas and in all phases of development. Our regulatory affairs services include the development and implementation of global regulatory strategic plans, regulatory agency meeting support, and electronic submissions to regulatory authorities around the world. We have the skill set and experience to guide your prime asset through any development challenges and along the ever-changing maze of regulatory filing pathways, to a position of full compliance, and high quality. Our expertise spans small molecules, peptides, oligonucleotides, biologics, monoclonal antibodies, antibody-drug conjugates, and cell and gene therapy products.